Fig. 4

Expression of Nanog/NFATc1/Osterix signaling pathway components at the tendon–bone interface at 12 weeks after anterior cruciate ligament reconstruction (ACLR). a Immunohistochemical staining for Nanog and quantification of the MOD at the tendon–bone interface. b mRNA expression of Nanog at the tendon–bone interface. c Immunohistochemical staining for NFATc1 and quantification of the MOD at the tendon–bone interface. d mRNA expression of NFATc1 at the tendon–bone interface. e Immunohistochemical staining for Osterix and quantification of the MOD at the tendon–bone interface. f mRNA expression of Osterix at the tendon–bone interface. g Protein expression of Nanog. h mRNA expression of Nanog. i Protein expression of NFATc1. j mRNA expression of NFATc1. k Protein expression of Osterix. l mRNA expression of Osterix. Data represent the mean ± SD (n = 5 in vivo, n = 3 in vitro). Scale bar = 50 μm. *p < 0.05, **p < 0.01. BMSCs bone marrow mesenchymal stem cells, De-BMSCs dedifferentiated osteogenic bone marrow mesenchymal stem cells, NFATc1 nuclear factor of activated T-cells c1, B bone, IF interface, T tendon